Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2017; 17(5):359-362
DOI: 10.5428/pcar20170512
Analysis of medication advice on lansoprazole injection and points for safety in clinical medication
1. ZHANG SuHeng(Department of Pharmacy,No.451 Hospital of PLA,Xi’an 710054,China 604207065@qq.com)
2. WANG XiaoNi(Department of Pharmacy,No.451 Hospital of PLA,Xi’an 710054,China )
3. KANG ALong(Department of Pharmacy,No.451 Hospital of PLA,Xi’an 710054,China kalong1900@163.com)
ABSTRACT  Objective: To analyze the rationality of clinical medication of lansoprazole injection and assess the risks involved,so as to provide evidence for clinical safe medication. Methods: Data concerning gender,age,aim/frequency/course of medication,and indications were collected from the randomly-selected 357 inpatients,and rationality,risks involved and points for safety in clinical medication were analyzed. Results: Of the 357 cases,235 cases (65.8%) were found to have drug abuse and excessive or non-standard medication,with the main problems of non-indication medication and excessively long treatment courses. The safety risks were mainly found in the prescription of medical advice,medical advice monitoring and drug infusion. Conclusion: The elimination of safety risks and improvement of safe medication could be achieved through the implementation of such measures as training and education,strengthening of medical advice monitoring and intensifying of quality control.
Welcome to PCAR! You are the number 84 reader of this article!
Please cite this article as:
ZHANG SuHeng,WANG XiaoNi,KANG ALong,. Analysis of medication advice on lansoprazole injection and points for safety in clinical medication[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2017; 17(5): 359-362.
References:
1. FENG Qun,ZHAO QingHua,LI MingJie,et al.Research progress in pharmacological and toxicological effects of lansoprozole[J].Chin J Drug Eval,2014,31(6):378-380.In Chinese with English abstract.
2. Pharmaceutical Administration Committee of Chinese Hospital Association.Pharmaceutical care for clinical application of proton pump inhibitors[M].Beijing:People’s Health Press,2013:4.In Chinese.
3. BAI Yu,LI YanQinq,REN Xu,et al.Expert advice on the prevention and treatment of stress ulcer[J].Natl Med J China,2015,95(20):1555-1557.In Chinese.
4. Geriatrics Society of Chinese Medical Association,Editorial Committee of Chinese Journal of Geriatrics.Expert consensus on rational use of proton pump inhibitor among old patients[J].Chin J Geriatr,2015,34(10):1045-1052.In Chinese.
5. Consensus Group of Chinese Experts on the Prevention and Treatment of Gastrointestinal Injury Induced by Antiplatelet Drugs.Chinese experts consensus on the prevention and treatment of gastrointestinal injury induced by antiplatelet drugs(2012 revision)[J].Chin J Intern Med,2013,52(3):264-268.In Chinese.
6. Editorial Committee of Chinese Journal of Digestion.Standards of diagnosis and treatment of peptic ulcer(2013,Shenzhen)[J].Chin J Dig,2014,34(2):73-76.In Chinese.
7. Clinical Medication Quality Control Center of Hunan Province.Guiding principles of clinical application of proton pump inhibitors in Hunan Provine (protocol)[J].Cent South Pharm,2016,14(7):673-683.In Chinese.
8. ZHANG JunWen,GAO Qing,TAO XiaoHong.Prevention of acute pancreatitis induced by ERCP with the union between somatostatin and proton pump inhibitor[J].Chongqing Med,2005,34(11):1662-1663.In Chinese with English abstract.
9. CHEN Wei,CHANG Ying,YANG Jun,et al.Clinical study of prophylactic effect of proton pump inhibitor combined with somatostatin and gabexate on post-ERCP pancreatitis and hyperamylasemia[J].Chin J Gastroenterol,2009,14(7):414-417.In Chinese with English abstract.
10. Branch Society of Digestive Endoscopy of Chinese Medical Association,Pancreatic Disease Committee of Chinese Medical Doctor Association.Expert consensus on pharmacological prevention of pancreatitis after endoscopic retrograde cholangiopancreatography (2015,Shanghai)[J].J Clin Hepatol,2016,32(5):830-834.In Chinese with English abstract.
11. SHI XiaoXiao,ZHENG SongBai.Research progress on application safety of long term proton pump inhibitor[J].Chin J New Drugs Clin Rem,2016,35(6):387-392.In Chinese with English abstract.
12. JIA Chen,WEI Qin,GAO XiaoHong,et al.Compatibility of lansoprazole for injection with four infusion solutions and incompatibility with other drugs[J].Chin J New Drugs,2014,23(19):2331-2334.In Chinese with English abstract.
13. QIAN LiFeng,CHEN CongZe,LU WenWen,et al.Incompatibility of sequential infusion of lansoprazole for injection and etamsylate for injection[J].Chin J Pract Nurs,2013,29(11):61.In Chinese.
14. QIU ShengHong,LIANG ZhiXian,WEI QiuDi,et al.Incompatibility of lansoprazole for injection with aminomethylbenzoic acid injection[J].Chin J Prac Nurs,2013,29(32):19.In Chinese.
15. CAI MeiRong.Incompatibility of lansoprazole for injection with compound amino acid injection(18AA-1)[J].Today Nurs,2013,March(last ten days):3.In Chinese.
16. WU XiaoLing,ZHOU MinHua,XIE YiDan,et al.Clinical safety evaluation and risk management of lansoprazole[J].China Pharmacy,2014,25(48):4531-4534.In Chinese with English abstract.
17. LEI ZhaoBao.Adverse reactions and rational use of proton pump inhibitors[J].World Chin J Digest,2016,24(23):3468-3475.In Chinese with English abstract.
18. BIAN JiaMing,ZENG Ming,WANG JinPing,et al. Utilization and rationality evaluation of proton pump inhibitors based on the HIS inpatients information[J]. Pharm Care Res,2016,16(4):271-276.In Chinese with English abstract.
19. XIA JinYun,WANG YuanYuan,CAO Bin.Compatibility of lansoprazole for injection with four infusion solutions[J].Guide China Med,2013,11(15):424-426.In Chinese with English abstract.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口